Szczepionki antynikotynowe jako metoda leczenia uzależnienia od nikotyny
Słowa kluczowe:
szczepionka, rzucanie palenia, immunoterapia, nikotyna, uzależnienieStreszczenie
Uzależnienie od nikotyny wciąż jest poważnym problemem, doprowadzającym do wielu poważnych konsekwencji zdrowotnych. Szczepienia przeciwko nikotynie stanowią obiecującą, nową koncepcję leczenia uzależnienia od nikotyny. Badania przedkliniczne wykazały, że mają one duży potencjał, jednak próby kliniczne nie przyniosły zadowalających wyników skuteczności w rzucaniu palenia. Prowadzone są jednak badania w celu zwiększenia skuteczności szczepionek, co w przyszłości może sprawić, że szczepionki staną się ważną terapią w leczeniu uzależnienia od nikotyny. Celem niniejszego rozdziału jest omówienie aspektów związanych z wykorzystaniem szczepionek antynikotynowych w leczeniu uzależnienia od nikotyny. W tym celu przeanalizowano związaną z tematem literaturę dostępną w bazach medycznych takich jak: PubMed, Google Scholar, Scopus.
Bibliografia
Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther. 2012;91(1):60-70. doi:10.1038/clpt.2011.281
Bloom BT, Bushell MJ. Vaccines against Drug Abuse-Are We There Yet?. Vaccines (Basel). 2022;10(6):860. Published 2022 May 27. doi:10.3390/vaccines10060860
Richesson D, Hoenig JM. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration (SAMHSA), 2021 PEP21-07-01-003
CBOS. Komunikat z badań. Palenie papierosów. 2019
Office of the Surgeon General (US); Office on Smoking and Health (US). The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2004
Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303. doi:10.1056/NEJMra0809890
Zatoński WA, Mańczuk M, Sulkowska U, Przewoźniak K. Palenie tytoniu a umieralność na choroby odtytoniowe w Europie Środkowo-Wschodniej. Zdrowie Publiczne i Zarządzanie. 2009;7(2).
Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25(6):317-324. doi:10.1016/j.tips.2004.04.006
Zalewska-Kaszubska J. Is immunotherapy an opportunity for effective treatment of drug addiction?. Vaccine. 2015;33(48):6545-6551. doi:10.1016/j.vaccine.2015.09.079
Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20(2):92-98. doi:10.1016/s0166-2236(96)10073-4
Nestler EJ. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005;8(11):1445-1449. doi:10.1038/nn1578
Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289-294. doi:10.1001/archpsyc.1986.01800030107013
Liu JF, Li JX. Drug addiction: a curable mental disorder?. Acta Pharmacol Sin. 2018;39(12):1823-1829. doi:10.1038/s41401-018-0180-x
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329. Published 2013 May 31. doi:10.1002/14651858.CD009329.pub2
Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391(6663):173-177. doi:10.1038/34413
Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57-71. doi:10.1146/annurev.pharmtox.48.113006.094742
Belongia EA, Naleway AL. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res. 2003;1(2):87-92. doi:10.3121/cmr.1.2.87
Francis MJ. Recent Advances in Vaccine Technologies. Vet Clin North Am Small Anim Pract. 2018;48(2):231-241. doi:10.1016/j.cvsm.2017.10.002
Myagkova MA, Morozova VS. Vaccines for substance abuse treatment: New approaches in the immunotherapy of addictions. Russian Chemical Bulletin. 2018;67(10):1781-1793. doi:10.1007/s11172-018-2290-5
Xu A, Kosten TR. Current status of immunotherapies for addiction. Ann N Y Acad Sci. 2021;1489(1):3-16. doi:10.1111/nyas.14329
Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine [published correction appears in Drug Des Devel Ther. 2011;5:487]. Drug Des Devel Ther. 2011;5:211-224. doi:10.2147/DDDT.S10033
Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000;65(1):191-198. doi:10.1016/s0091-3057(99)00206-3
Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol. 2003;3(7):957-970. doi:10.1016/S1567-5769(03)00094-8
Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22(10):809-819. doi:10.1016/s0192-0561(00)00042-4
Cerny EH, Lévy R, Mauel J, et al. Preclinical development of a vaccine 'against smoking'. Onkologie. 2002;25(5):406-411. doi:10.1159/000067433
Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction. 2014;109(8):1252-1259. doi:10.1111/add.12573
Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers [published correction appears in Clin Pharmacol Ther. 2006 Apr;79(4):396]. Clin Pharmacol Ther. 2005;78(5):456-467. doi:10.1016/j.clpt.2005.08.007
Esterlis I, Hannestad JO, Perkins E, et al. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013;170(4):399-407. doi:10.1176/appi.ajp.2012.12060793
Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392-399. doi:10.1038/clpt.2010.317
Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines. 2013;12(3):333-342. doi:10.1586/erv.13.13
Nicotine vaccination and nicotinic receptor occupancy - full text view. Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00996034?term=NCT00996034&draw=2&rank=1.
Havermans A, Vuurman EF, van den Hurk J, Hoogsteder P, van Schayck OC. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Addiction. 2014;109(8):1260-1267. doi:10.1111/add.12577
Ottney AR. Nicotine conjugate vaccine as a novel approach to smoking cessation. Pharmacotherapy. 2011;31(7):703-713. doi:10.1592/phco.31.7.703
Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012;2012(8):CD007072. Published 2012 Aug 15. doi:10.1002/14651858.CD007072.pub2
Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031-2040. doi:10.1002/eji.200526285
Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs. 2007;16(11):1775-1783. doi:10.1517/13543784.16.11.1775
Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547. Published 2008 Jun 25. doi:10.1371/journal.pone.0002547
Tonstad S, Heggen E, Giljam H, et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res. 2013;15(9):1492-1501. doi:10.1093/ntr/ntt003
Smoking habits, a vaccine and varenicline. safety, immunogenicity and some early signs of efficacy for the nicotine vaccine, Ta-Nic. Campbell Bunce. Available at: http://www.uknscc.org/2005_UKNSCC/speakers/campbell_bunce.html (Accessed: January 5, 2023).
Desai RI, Bergman J. Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys. Neuropsychopharmacology. 2015;40(9):2207-2216. doi:10.1038/npp.2015.64
Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014;69:553-580. doi:10.1016/B978-0-12-420118-7.00014-7
Roseman C, Truedsson L, Kapetanovic MC. The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis. Arthritis Res Ther. 2012;14(4):R170. Published 2012 Jul 23. doi:10.1186/ar3923
Crothers K, Daly KR, Rimland D, et al. Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers. Clin Vaccine Immunol. 2011;18(3):380-386. doi:10.1128/CVI.00421-10
Lindblom N, de Villiers SH, Semenova S, et al. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(3):182-194. doi:10.1007/s00210-005-0019-0
Alzhrani RF, Xu H, Valdes SA, Cui Z. Intranasal delivery of a nicotine vaccine candidate induces antibodies in mouse blood and lung mucosal secretions that specifically neutralize nicotine. Drug Dev Ind Pharm. 2020;46(10):1656-1664. doi:10.1080/03639045.2020.1820033
Fraleigh NL, Lewicky JD, Martel AL, Diaz-Mitoma F, Le HT. Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine. Vaccines (Basel). 2021;9(2):118. Published 2021 Feb 3. doi:10.3390/vaccines9020118
Le HT, Fraleigh NL, Lewicky JD, et al. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides. Molecules. 2020;25(6):1290. Published 2020 Mar 12. doi:10.3390/molecules25061290
de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 2013;31(52):6185-6193. doi:10.1016/j.vaccine.2013.10.051
Hoogsteder PH, Kotz D, van Spiegel PI, et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health. 2012;12:1052. Published 2012 Dec 6. doi:10.1186/1471-2458-12-1052
Zapowiedzi
26 marca 2023
Prawa autorskie (c) 2023 Magdalena Stencel; Michał Janik, Błażej Pilarski, Małgorzata Planer, Natalia Denisiewicz, Piotr Dudek
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
